Recently, two ALK-TKIs, crizotinib and ceritinib, have been approved for the treatment of advanced ALK-positive NSCLC patients, thus the use of these drugs is anticipated to be increased in anti-cancer treatment and clinical studies. Here, ALK is linked to cancer.